Mouse triple-negative primary glioblastoma cell strain and application thereof

Abstract

The invention provides a mouse triple-negative primary glioblastoma cell strain G422TN-GBM, which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2020267. The mouse triple-negative primary glioblastoma cell strain provided by the invention has the following molecular characteristics: an IDH1 / 2 wild type is adopted, Chr1 / 19 is complete, TERT promoter mutation is negative, and ATRX mutation and Trp53 mutation are accompanied. A glioblastoma animal model established by the cell strain has high replicability and stability, can simulate the clinical treatment response of glioblastoma at each stage, can be used for anti-tumor drug screening, new therapy pre-clinical curative effect evaluation and single-drug and combined treatment scheme curative effect evaluation, and has a wide application prospect. And evaluating the early, middle and late treatment effects of the malignant glioma.

Description

technical field [0001] The invention relates to a cell line, in particular to a glioblastoma cell line, in particular to a mouse triple-negative primary glioblastoma cell line and its application. Background technique [0002] Glioblastoma (GBM) is the most malignant primary brain tumor. An important malignant pathological feature of GBM is that it spreads to the surrounding and shows infiltrative growth, and the boundary with the surrounding normal tissue is unclear. It is difficult to be completely removed by surgery. [1] . Temozolomide (TMZ) concurrent chemoradiotherapy combined with 6-month temozolomide adjuvant chemotherapy (RT) after glioma surgery is currently the standard treatment for newly diagnosed glioblastoma. [2] . After conventional surgery, radiotherapy and chemotherapy combined treatment, the prognosis is poor, and the median survival of patients is only extended from 12 months to about 15 months, that is, the treatment is effective but very limited. Ther...

AI Technical Summary

Problems solved by technology

Therefore, the use of survival time in the CT-2A model to judge drug efficacy may have great uncertainty

Images